PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Researchers hope newly discovered gene interaction could lead to novel cancer therapies

2013-12-13
(Press-News.org) Contact information: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Researchers hope newly discovered gene interaction could lead to novel cancer therapies

Scientists from Virginia Commonwealth University Massey Cancer Center have revealed how two genes interact to kill a wide range of cancer cells. Originally discovered by the study's lead investigator Paul B. Fisher, M.Ph., Ph.D., the genes known as mda-7/IL-24 and SARI could potentially be harnessed to treat both primary and metastatic forms of brain, breast, colon, lung, ovary, prostate, skin and other cancers.

In the study, recently published in the online version of the journal Cancer Research, Fisher's team found that forced expression of MDA-7/IL-24 (melanoma differentiation associated gene-7/interlukin-24) stimulates SARI (suppressor of AP-1, induced by interferon) expression in what is known as an autocrine/paracrine loop, which ultimately causes cancer cells to undergo a form of cell suicide known as apoptosis. Autocrine/paracrine loops occur when the expression of a particular gene or its encoded protein causes cells to secrete molecules that bind to surface receptors and force the expression of more of the same protein in an ongoing cycle.

"Many previous studies show that MDA-7/IL-24 can selectively kill diverse cancer cells through multiple mechanisms, but what was unclear was how exactly MDA-7/IL-24 interacted with other genes to promote cancer toxicity," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center, and chairman of the Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine (VIMM) at VCU School of Medicine. "Our study uncovered multiple signaling pathways used by MDA-7/IL-24 that facilitate cancer cell death through the induction of SARI."

Fisher and his team identified an existing combination of receptors, IL-20R1 and IL-20R2, and a discovered new combination of receptors, IL-22R1 and IL-20R1, through which signaling occurs to induce the MDA-7/IL-24 autocrine/paracrine loop. Once activated by the MDA-7/IL-24 protein, these receptors cause both normal and cancer cells to produce and secrete the MDA-7/IL-24 protein, which, in turn, activates SARI. The process was shown to culminate in apoptosis in cancer cells. Normal, healthy cells were not affected in the experiments.

The researchers are now focusing on developing small molecule drugs that induce MDA-7/IL-24 and/or SARI in cancer cells. They have also been experimenting with cancer-selective replicating viruses that seek out cancer cells and infect them with the toxic genes—an approach that has already been successfully employed in a phase 1 clinical trial using engineered viruses that deliver MDA-7/IL-24.

"This study helped us better understand how MDA-7/IL-24 works to kill a broad range of cancer cells through the induction of SARI," says Fisher. "In addition to giving us another target for the development of new therapies, our research also suggests that we may be able to monitor the expression of SARI in order to determine the effectiveness of future therapies under development that target MDA-7/IL-24."



INFORMATION:



Fisher collaborated on this research with Praveen Bhoopathi, Ph.D., postdoctoral research scientist in the Department of Human and Molecular Genetics at the VCU School of Medicine; Swadesh K. Das, Ph.D., instructor in the VCU Department of Human and Molecular Genetics and VIMM member; Devanand Sarkar, M.B.B.S., Ph.D., Harrison Research Scholar and member of the Cancer Molecular Genetics research program at VCU Massey, associate professor in the VCU Department of Human and Molecular Genetics and associate scientific director of cancer therapeutics at VIMM; Luni Emdad, M.B.B.S., Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member; Santanu Dasgupta, Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member; and Rupesh Dash, Ph.D., former postdoctoral research scientist in the VCU Department of Human and Molecular Genetics and now assistant professor at the Institute of Life Sciences in Bhubaneshwar, India.

This research was supported by National Institutes of Health grants 5 R01 CA097318, P01 CA104177 and 1 R01CA127641; and, in part, by VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.

The full manuscript of this study is available online at: http://cancerres.aacrjournals.org/content/early/2013/11/26/0008-5472.CAN-13-1062.full.pdf+html

News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.

About VCU Massey Cancer Center

VCU Massey Cancer Center is one of only 68 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers the most cancer clinical trials in Virginia and serves patients at 10 locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at http://www.massey.vcu.edu or call 877-4-MASSEY for more information.

About VCU and the VCU Medical Center

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.vcu.edu.



ELSE PRESS RELEASES FROM THIS DATE:

Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells

2013-12-13
Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells SAN ANTONIO — For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line ...

New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer

2013-12-13
New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer SAN ANTONIO — The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete ...

New combination therapy fails to delay progression of advanced breast cancer

2013-12-13
New combination therapy fails to delay progression of advanced breast cancer SAN ANTONIO — Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced ...

Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer

2013-12-13
Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer SAN ANTONIO — Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial ...

New presurgery treatment combination more effective for women with triple-negative breast cancer

2013-12-13
New presurgery treatment combination more effective for women with triple-negative breast cancer SAN ANTONIO — Adding the chemotherapy drug carboplatin and/or the antibody therapy bevacizumab to standard presurgery chemotherapy increased the ...

Additional drug shows promise for women with triple-negative breast cancer

2013-12-13
Additional drug shows promise for women with triple-negative breast cancer SAN ANTONIO— In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy ...

Study shows new paradigm in breast cancer research

2013-12-13
Study shows new paradigm in breast cancer research Promising drugs put on fast track MAYWOOD, Ill. – The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during ...

True story: Not everyone lies frequently

2013-12-13
True story: Not everyone lies frequently Many liars prove honest in their dishonesty Washington, DC (December 10, 2013) – Does everybody lie? We are taught that this is common sense and that most people tell little white lies. But perhaps this isn't ...

Defending medical oncology to assure quality care for cancer patients

2013-12-13
Defending medical oncology to assure quality care for cancer patients ESMO releases position paper on the role of medical oncologists in cancer care to ensure patient's access to optimal care Medical oncologists have a vital role to play in cancer care, particularly ...

Zebrafish help decode link between calcium deficiency and colon cancer

2013-12-13
Zebrafish help decode link between calcium deficiency and colon cancer ANN ARBOR—A tiny, transparent fish embryo and a string of surprises led scientists to a deeper understanding of the perplexing link between low calcium and colon cancer. By studying zebrafish ...

LAST 30 PRESS RELEASES:

Scientists track evolution of pumice rafts after 2021 underwater eruption in Japan

The future of geothermal for reliable clean energy

Study shows end-of-life cancer care lacking for Medicare patients

Scented wax melts may not be as safe for indoor air as initially thought, study finds

Underwater mics and machine learning aid right whale conservation

Solving the case of the missing platinum

Glass fertilizer beads could be a sustained nutrient delivery system

Biobased lignin gels offer sustainable alternative for hair conditioning

Perovskite solar cells: Thermal stresses are the key to long-term stability

University of Houston professors named senior members of the National Academy of Inventors

Unraveling the mystery of the missing blue whale calves

UTA partnership boosts biomanufacturing in North Texas

Kennesaw State researcher earns American Heart Association award for innovative study on heart disease diagnostics

Self-imaging of structured light in new dimensions

Study highlights successes of Virginia’s oyster restoration efforts

Optimism can encourage healthy habits

Precision therapy with microbubbles

LLM-based web application scanner recognizes tasks and workflows

Pattern of compounds in blood may indicate severity of gestational hypertension and preeclampsia

How does innovation policy respond to the challenges of a changing world?

What happens when a diet targets ultra-processed foods?

University of Vaasa, Finland, conducts research on utilizing buildings as energy sources

Stealth virus: Zika virus builds tunnels to covertly infect cells of the placenta

The rising tide of sand mining: a growing threat to marine life

Contemporary patterns of end-of-life care among Medicare beneficiaries with advanced cancer

Digital screen time and nearsightedness

Postoperative weight loss after anti-obesity medications and revision risk after joint replacement

New ACS research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

New frailty measurement tool could help identify vulnerable older adults in epic

Co-prescribed stimulants, opioids linked to higher opioid doses

[Press-News.org] Researchers hope newly discovered gene interaction could lead to novel cancer therapies